Tifenn Wauquier
Research Subjects
Tifenn Wauquier has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Alice Lepelley
Université Paris Cité, Paris, France
2 shared publications - Marie-Louise Frémond
Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, Paris, France
2 shared publications - Yanick Joseph Crow
MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK
2 shared publications - Alexandre Belot
Centre International de Recherche en Infectiologie, Inserm, U1111, CNRS, UMR5308, École Normale Supérieure de Lyon, Lyon, France
1 shared publication - Alix de Becdelièvre
INSERM, Unité U955, Créteil, France
1 shared publication - Anne Puel
Necker Branch, INSERM UMR 1163 3 Laboratory of Human Genetics of Infectious Diseases, Institut Imagine, Université Paris Cité Paris
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 10 March 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (4)
The STING HAQ haplotype and clinical non-penetrance in COPA syndrome
COPA syndrome is a rare monogenic autoinflammatory disease due to heterozygous mutations in COPA, encoding the coatomer subunit α. COPA syndrome demonstrates phenotypic overlap with STING-associated vasculopathy with onset in infancy (SAVI), the latter due to gain-of-function mutations in STING1. Indeed, STING activation is a key driver of the pathogenesis of COPA syndrome, and a recent report suggested that the presence of the common HAQ STING allele confers complete protection against the development of clinical disease in the context of pathogenic heterozygous mutations in COPA. Given the potential significance of this result for patient management, we investigated the STING HAQ haplotype status of a separate cohort of individuals segregating pathogenic mutations in COPA. In doing so, we ascertained five HAQ-negative, clinically asymptomatic individuals aged 30, 39, 39, 42, and 43 years at last evaluation, and an HAQ-positive male with kidney disease that we consider most likely attributable to the recurrent R233H mutation in COPA. Our findings challenge the suggestion that STING haplotype status is the sole determinant of clinical penetrance in COPA syndrome.
- 10 March 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (4)
Top Cited PapersOpen AccessThe STING HAQ haplotype and clinical non-penetrance in COPA syndrome
COPA syndrome is a rare monogenic autoinflammatory disease due to heterozygous mutations in COPA, encoding the coatomer subunit α. COPA syndrome demonstrates phenotypic overlap with STING-associated vasculopathy with onset in infancy (SAVI), the latter due to gain-of-function mutations in STING1. Indeed, STING activation is a key driver of the pathogenesis of COPA syndrome, and a recent report suggested that the presence of the common HAQ STING allele confers complete protection against the development of clinical disease in the context of pathogenic heterozygous mutations in COPA. Given the potential significance of this result for patient management, we investigated the STING HAQ haplotype status of a separate cohort of individuals segregating pathogenic mutations in COPA. In doing so, we ascertained five HAQ-negative, clinically asymptomatic individuals aged 30, 39, 39, 42, and 43 years at last evaluation, and an HAQ-positive male with kidney disease that we consider most likely attributable to the recurrent R233H mutation in COPA. Our findings challenge the suggestion that STING haplotype status is the sole determinant of clinical penetrance in COPA syndrome.
- Open Access
- 4 June 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 1 (2)
Spondyloenchondrodysplasia: An enigmatic immuno-osseus type I interferonopathy
Spondyloenchondrodysplasia (SPENCD) is a rare immuno-osseus disease due to biallelic mutations in ACP5, resulting in a loss of tartrate-resistant acid phosphatase (TRAP) activity and enhanced type I interferon signalling. While TRAP was identified in the 1950s, ACP5 was cloned in the 1990s, an Acp5 knockout mouse was reported in 1996, and >3,000 articles are retrievable on PubMed using the terms “tartrate-resistant acid phosphatase” + “TRAP”, the immunopathology of SPENCD remains unclear. Here we describe the clinical phenotype and molecular architecture of SPENCD, review the biology of TRAP, and consider how TRAP deficiency leads to disturbed innate immunity.
- 4 June 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 1 (2)
Open AccessSpondyloenchondrodysplasia: An enigmatic immuno-osseus type I interferonopathy
Spondyloenchondrodysplasia (SPENCD) is a rare immuno-osseus disease due to biallelic mutations in ACP5, resulting in a loss of tartrate-resistant acid phosphatase (TRAP) activity and enhanced type I interferon signalling. While TRAP was identified in the 1950s, ACP5 was cloned in the 1990s, an Acp5 knockout mouse was reported in 1996, and >3,000 articles are retrievable on PubMed using the terms “tartrate-resistant acid phosphatase” + “TRAP”, the immunopathology of SPENCD remains unclear. Here we describe the clinical phenotype and molecular architecture of SPENCD, review the biology of TRAP, and consider how TRAP deficiency leads to disturbed innate immunity.